These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31357122)

  • 21. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.
    Costelloe L; Jones J; Coles A
    Expert Rev Neurother; 2012 Mar; 12(3):335-41. PubMed ID: 22364332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases.
    Comini-Frota ER; Campos APF; Neto APG; Christo PP
    Mult Scler Relat Disord; 2020 Sep; 44():102181. PubMed ID: 32531751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 24. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
    Richter S; Wagner B; Celius EG
    J Neurol; 2019 May; 266(5):1270-1271. PubMed ID: 30805797
    [No Abstract]   [Full Text] [Related]  

  • 25. Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis.
    Madeley J; Hodges G; Birchley A
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30337289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis.
    Li Z; Richards S; Surks HK; Jacobs A; Panzara MA
    Clin Exp Immunol; 2018 Dec; 194(3):295-314. PubMed ID: 30144037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocrelizumab for Post-Alemtuzumab Paradoxical Disease Activity in Highly Active Multiple Sclerosis.
    Adamec I; Habek M
    Clin Neuropharmacol; 2022 Sep-Oct 01; 45(5):139-141. PubMed ID: 36093911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort.
    Cossburn M; Pace AA; Jones J; Ali R; Ingram G; Baker K; Hirst C; Zajicek J; Scolding N; Boggild M; Pickersgill T; Ben-Shlomo Y; Coles A; Robertson NP
    Neurology; 2011 Aug; 77(6):573-9. PubMed ID: 21795656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Ruck T; Pfeuffer S; Schulte-Mecklenbeck A; Gross CC; Lindner M; Metze D; Ehrchen J; Sondermann W; Pul R; Kleinschnitz C; Wiendl H; Meuth SG; Klotz L
    Neurology; 2018 Dec; 91(24):e2233-e2237. PubMed ID: 30404783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary embolism during the third cycle of alemtuzumab in a patient with relapsing multiple sclerosis.
    Habek M; Ruška B; Pavičić T; Alduk AM; Gabelić T; Adamec I
    Mult Scler Relat Disord; 2019 Oct; 35():5-6. PubMed ID: 31276912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab.
    Clerico M; De Mercanti S; Artusi CA; Durelli L; Naismith RT
    Mult Scler; 2017 May; 23(6):874-876. PubMed ID: 28290755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration.
    Hoffman BM; Zeid NA; Alam U; Caress JB
    Mult Scler Relat Disord; 2019 Jan; 27():131-132. PubMed ID: 30384197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report.
    Romero A; Midaglia L; Salcedo MT; Viladomiu L; Guillén E; Bajaña I; Escolà-Vergé L; Tintoré M; Montalban X; Len O
    Mult Scler Relat Disord; 2020 May; 40():101973. PubMed ID: 32028116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.
    Midaglia L; Gratacòs M; Caronna E; Raguer N; Sastre-Garriga J; Montalban X; Tintoré M
    Neurology; 2018 Sep; 91(13):622-624. PubMed ID: 30143565
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.
    Iovino A; Aruta F; Carotenuto A; Manganelli F; Iodice R
    Mult Scler Relat Disord; 2019 Feb; 28():98-100. PubMed ID: 30580038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detecting and predicting neutralization of alemtuzumab responses in MS.
    Saxena G; Moore JM; Jones M; Pryce G; Ali L; Leisegang GR; Vijay V; Loveless S; Robertson NP; Schmierer K; Giovannoni G; Gnananpavan S; Baker D; Tallantyre EC; Kang AS
    Neurol Neuroimmunol Neuroinflamm; 2020 Jul; 7(4):. PubMed ID: 32499328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.